Advertisement

Non-Small Cell Lung Cancer

  • E. E. W. Cohen
  • E. E. Vokes
Chapter
  • 110 Downloads

Abstract

Lung cancer represents the leading cause of cancer mortality in the United States in both sexes [1]. With approximately 170, 000 people diagnosed in 2000, lung cancer accounts for almost a third of all cancer deaths. This is partly because of the strong correlation of survival with stage and because over twothirds of patients present with locally advanced or metastatic disease (Table 28.1). Among men in the industrialized world, the incidence of lung cancer has been slowly decreasing for the last 3 decades. However, the incidence in women in these countries and in both sexes in the developing world has been increasing, paralleling smoking behavior.

Keywords

Lung Cancer Clin Oncol Radiat Oncol Biol Phys Radiation Therapy Oncology Group Nonsmall Cell Lung Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenlee RT, Murray T, Bolden S et al (2000) Cancer statistics, 2000. CA Cancer J Clin 50:7–33PubMedCrossRefGoogle Scholar
  2. 2.
    Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717PubMedCrossRefGoogle Scholar
  3. 3.
    Paesmans M, Sculier JP, Libert P et al (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13:1221–1230PubMedGoogle Scholar
  4. 4.
    Albain KS, Crowley JJ, LeBlanc M et al (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618–1626PubMedGoogle Scholar
  5. 5.
    Sone S, Takashima S, Li F et al (1998) Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 351:1242–1245PubMedCrossRefGoogle Scholar
  6. 6.
    Henschke CI, McCauley DI, Yankelevitz DF et al (1999) Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354:99–105PubMedCrossRefGoogle Scholar
  7. 7.
    Gupta NC, Maloof J, Gunel E (1996) Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37:943–948PubMedGoogle Scholar
  8. 8.
    Bury T, Dowlati A, Paulus P et al (1996) Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 9:410–414PubMedCrossRefGoogle Scholar
  9. 9.
    Bury T, Paulus P, Dowlati A et al (1996) Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 9: 2560–2564PubMedCrossRefGoogle Scholar
  10. 10.
    Dunagan D, Chin R Jr, McCain T et al (2001) Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer. Chest 119:333–339PubMedCrossRefGoogle Scholar
  11. 11.
    De Leyn P, Vansteenkiste J, Cuypers P et al (1997) Role of cervical mediastinoscopy in staging of non-small cell lung cancer without enlarged mediastinal lymph nodes on CT scan. Eur J Cardiothorac Surg 12:706–712PubMedCrossRefGoogle Scholar
  12. 12.
    Grunenwald D, Le Chevalier T (1997) Re: Stage IIIA category of non-small-cell lung cancer: a new proposal. J Natl Cancer Inst 89:88–89PubMedCrossRefGoogle Scholar
  13. 13.
    Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on 16 May 1997 by the American Society of Clinical Oncology. (1997) J Clin Oncol 15:2996–3018Google Scholar
  14. 14.
    American Thoracic Society and The European Respiratory Society (1997) Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med 156:320–332Google Scholar
  15. 15.
    Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 NO non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615–622; discussion 622-623PubMedCrossRefGoogle Scholar
  16. 16.
    Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials (see comments). BMJ 311:899–909CrossRefGoogle Scholar
  17. 17.
    Feld R, Rubinstein L, Thomas PA (1993) Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-smallcell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst 85:299–306PubMedCrossRefGoogle Scholar
  18. 18.
    Depierre A, Milleron B, Chevret S et al (2000) French phase III trial of preoperative chemotherapy in resectable stage I (except T1NO), II, IIIa, non-small cell lung cancer, 9th world conference on lung cancer. Elsevier Science, TokyoGoogle Scholar
  19. 19.
    Pisters KM, Ginsberg RJ, Giroux DJ et al (2000) Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 119:429–439PubMedCrossRefGoogle Scholar
  20. 20.
    PORT Meta-analysis Trialists Group (1998) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352:257–263CrossRefGoogle Scholar
  21. 21.
    Dillman RO, Seagren SL, Propert KJ et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer (see comments). N Engl J Med 323:940–945PubMedCrossRefGoogle Scholar
  22. 22.
    Le Chevalier T, Arriagada R, Quoix E et al (1991) Radiotherapy alone versus combined chemotherapy and ratherapy in stagesIIIaandIIIb non-smallcell lung cancer. analysis of a randomized trial in 353 patients (see comments). J Natl Cancer Inst 83:417–423PubMedCrossRefGoogle Scholar
  23. 23.
    Grunenwald DH (2000) Surgery for advanced stage lung cancer. Semin Surg Oncol 18:137–142PubMedCrossRefGoogle Scholar
  24. 24.
    Rosell R, Gomez-Codina J, Camps C et al (1999) Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer Inst83:417–424Google Scholar
  25. 25.
    Roth JA, Atkinson EN, Fossella F et al (1998) Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with mother apy in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21:1–6PubMedCrossRefGoogle Scholar
  26. 26.
    Pisters KM, Kris MG, Gralla RJ et al (1994) Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer. J Surg Oncol 56:236–241PubMedCrossRefGoogle Scholar
  27. 27.
    Elias AD, Herndon J, Kumar P et al (1997) A phase III comparison of “best local-regional therapy” with or without chemotherapy (CT) for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC): preliminary results (abstract). Proceedings of the American Society of Clinical Oncology, p448AGoogle Scholar
  28. 28.
    Grunenwald DH, Andre F, Le Pechoux C et al (2001) Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 122:796–802PubMedCrossRefGoogle Scholar
  29. 29.
    Albain KS, Rusch VW, Crowley JJ et al (1995) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880–1892PubMedGoogle Scholar
  30. 30.
    Eberhardt W, Wilke H, Stamatis G et al (1998) Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-smallcell lung cancer: mature results of a phase II trial. J Clin Oncol 16:622–634PubMedGoogle Scholar
  31. 31.
    Grunenwald D, Mazel C, Girard P et al (1996) Total vertebrectomy for en bloc resection of lung cancer invading the spine. Ann Thorac Surg 61:723–725; discussion 725-726PubMedCrossRefGoogle Scholar
  32. 32.
    Dillman RO, Herndon J, Seagren SL et al (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial (see comments). J Natl Cancer Inst 88:1210–1215PubMedCrossRefGoogle Scholar
  33. 33.
    Pritchard RS, Anthony SP (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis (published erratum appears in Ann Intern Med 1997,126:670). Ann Intern Med 125: 723–729PubMedGoogle Scholar
  34. 34.
    Marino P, Preatoni A, Cantoni A (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. A meta-analysis (see comments). Cancer 76:593–601PubMedCrossRefGoogle Scholar
  35. 35.
    Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699PubMedGoogle Scholar
  36. 36.
    Clamon G, Herndon J, Cooper R et al (1999) Radiosensitization with caroplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group (see comments). J Clin Oncol 17:4–11PubMedGoogle Scholar
  37. 37.
    Vokes EE (2001) Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. Oncologist 6:25–27PubMedCrossRefGoogle Scholar
  38. 38.
    Mehta M, Scrimger R, Mackie R et al (2001) A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 49:23–33PubMedCrossRefGoogle Scholar
  39. 39.
    Tannehill SP, Mehta MP, Larson M et al (1997) Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-smallcell lung cancer: results of a phase II trial. J Clin Oncol 15:2850–2857PubMedGoogle Scholar
  40. 40.
    Atagi S, Kawahara M, Ogawara M et al (2000) Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Jpn J Clin Oncol 30:59–64PubMedCrossRefGoogle Scholar
  41. 41.
    Lau DH, Crowley JJ, Gandara DR et al (1998) Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 16:3078–3081PubMedGoogle Scholar
  42. 42.
    Rapp E, Pater JL, Willan A et al (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641PubMedGoogle Scholar
  43. 43.
    Goodwin PJ, Shepherd FA (1998) Economic issues in lung cancer a. J Clin Oncol 16:3078–3081Google Scholar
  44. 44.
    Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11:1866–1872PubMedGoogle Scholar
  45. 45.
    Souquet PJ, Chauvin F, Boissel JP et al (1993) Polychemotherapy in advanced non-small cell lung cancer: a metaanalysis. Lancet 342:19–21PubMedCrossRefGoogle Scholar
  46. 46.
    Gándara DR, Crowley J, Livingston RB et al (1993) Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11:873–878PubMedGoogle Scholar
  47. 47.
    Lilenbaum RC, Langenberg P, Dickersin K (1998) Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer 82:116–126PubMedCrossRefGoogle Scholar
  48. 48.
    Breathnach OS, Freidlin B, Conley B et al (2001) Twentytwo years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1734–1742PubMedGoogle Scholar
  49. 49.
    Choy H, Shyr Y, Cmelak AJ et al (2000) Patterns of practice survey for nonsmall cell lung carcinoma in the US. Cancer 88:1336–1346PubMedCrossRefGoogle Scholar
  50. 50.
    Belani CP, Natale RB, Lee JS et al (1998) Randomized phase III Trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic Non-Small Cell Lung Cancer (NSCLC) (abstract). American Society of Clinical Oncology, Los Angeles, p 455AGoogle Scholar
  51. 51.
    Kelly K, Crowley J, Bunn PA et al (1999) A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced Non-Small Cell Lung Cancer (NSCLC): a Southwest Oncology Group (SWOG) Trial (abstract). Proceedings of the American Society of Clinical Oncology, Atlanta, p 461AGoogle Scholar
  52. 52.
    Schiller JH, Harrington D, Sandier A et al (2000) A randomized phase III trial of four chemotherapy regimens in advanced non-small-cell lung cancer.JClin (abstract). Proceedings of the American Society of Clinical Oncology, New Orleans, p 1AGoogle Scholar
  53. 53.
    Scagliotti G, De Marinis F, Rinaldi M et al (2001) Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer (abstract). trac of t). American Society of Clinical Oncology, San Francisco, p 308AGoogle Scholar
  54. 54.
    Georgoulias V, Papadakis E, Alexopoulos A et al (1999) Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of a multicenter randomized phase II eding softhe American Society of Clinical Oncology, Atlanta, p 461AGoogle Scholar
  55. 55.
    Kosmidis P, Mylonakis N, Dimopoulos A et al (2000) Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group. Semin Oncol 27:3–8PubMedGoogle Scholar
  56. 56.
    Van Meerbeeck J, Smit E, Lianes P et al (2001) A EORTC randomized phase III trial of three chemotherapy regimens in advanced Non-Small Cell Lung Cancer (NSCLC) (abstract). American Society of Clinical Oncology, San Francisco, p 308AGoogle Scholar
  57. 57.
    Buccheri GF, Ferrigno D, Curcio A et al (1989) Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 63:428–432PubMedCrossRefGoogle Scholar
  58. 58.
    Smith IE, O’B rien ME, Talbot DC et al (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336–1343PubMedGoogle Scholar
  59. 59.
    Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103PubMedGoogle Scholar
  60. 60.
    Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354–2362PubMedGoogle Scholar
  61. 61.
    Huisman C, Smit EF, Giaccone G et al (2000) Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 18:3722–3730PubMedGoogle Scholar
  62. 62.
    The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72CrossRefGoogle Scholar
  63. 63.
    Frasci G, Lorusso V, Panza N et al (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529–2536PubMedGoogle Scholar
  64. 64.
    Gridelli C, Perrone F, Cigolari S et al (2001) The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients (abstract). American Society of Clinical Oncology, San Francisco, p 308AGoogle Scholar
  65. 65.
    Granone P, Margaritora S, D’Andrilli A et al (2001) Non-small cell lung cancer with single brain metastasis: the role of surgical treatment. Eur J Cardiothorac Surg 20: 361–366PubMedCrossRefGoogle Scholar
  66. 66.
    Shahidi H, Kvale PA (1996) Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Chest 109:271–276PubMedCrossRefGoogle Scholar
  67. 67.
    Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500PubMedCrossRefGoogle Scholar
  68. 68.
    Patchell RA, Tibbs PA, Régine WF et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485–1489PubMedCrossRefGoogle Scholar
  69. 69.
    Niiranen A, Niitamo-Korhonen S, Kouri M et al (1992) Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol 10: 1927–1932PubMedGoogle Scholar
  70. 70.
    Holmes EC, Gail M (1986) Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 4:710–715PubMedGoogle Scholar
  71. 71.
    The Lung Cancer Study Group (1988) The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 6:9–17Google Scholar
  72. 72.
    Dautzenberg B, Chastang C, Arriagada R et al (1995) Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d’Etude et de Traitement des Cancers Bronchiques). Cancer 76:779–786PubMedCrossRefGoogle Scholar
  73. 73.
    Keller SM, Adak S, Wagner H et al (2000) A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343:1217–1222PubMedCrossRefGoogle Scholar
  74. 74.
    Ohta M, Tsuchiya R, Shimoyama M et al (1993) Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group. J Thorac Cardiovasc Surg 106:703–708PubMedGoogle Scholar
  75. 75.
    Mattson K, Abratt R, Ten GV et al (2001) Docetaxel as neoadjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study. Lung Cancer 34[Suppl 4]:21–23CrossRefGoogle Scholar
  76. 76.
    Morton RF, Jett JR, McGinnis WL et al (1991) Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial (see comments). Ann Intern Med 115:681–686PubMedGoogle Scholar
  77. 77.
    Crino L, Latini P, Meacci M et al (1993) Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 4:847–851PubMedGoogle Scholar
  78. 78.
    Schaake-Koning C, van den Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer (see comments). N Engl J Med 326:524–530PubMedCrossRefGoogle Scholar
  79. 79.
    Blanke C, Ansari R, Mantravadi R et al (1995) Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 13:1425–1429PubMedGoogle Scholar
  80. 80.
    Trovo MG, Minatel E, Franchin G et al (1992) Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer (see comments). Int J Radiat Oncol BiolPhys 24:11–15CrossRefGoogle Scholar
  81. 81.
    Cox JD, Azarnia N, Byhardt RW et al (1990) A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543–1555PubMedGoogle Scholar
  82. 82.
    Saunders M, Dische S, Barrett A et al (1999) Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee (see comments). Radiother Oncol 52:137–148PubMedCrossRefGoogle Scholar
  83. 83.
    Sause W, Kolesar P, Taylor SI et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358–364PubMedCrossRefGoogle Scholar
  84. 84.
    Komaki R, Scott C, Ettinger D et al (1997) Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 38:149–155PubMedCrossRefGoogle Scholar
  85. 85.
    Curran W, Scott C, Langer C et al (2000) Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: report of Radiation Therapy Oncology Group 9410, 9th World Conference on Lung Cancer (abstract no. 303). Lung Cancer, 29[Suppl. 1]:93CrossRefGoogle Scholar
  86. 86.
    Jeremic B, Shibamoto Y, Acimovic L et al (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452–458PubMedGoogle Scholar
  87. 87.
    Jeremic B, Shibamoto Y, Acimovic L et al (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14:1065–1070PubMedGoogle Scholar
  88. 88.
    Ball D, Bishop J, Smith J et al (1999) A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multicentre trial (see comments). Radiother Oncol 52:129–136PubMedCrossRefGoogle Scholar
  89. 89.
    Hayman JA, Martel MK, Ten Haken RK et al (2001) Dose escalation in non-small-cell lung cancer using three-dimensional conformai radiation therapy: update of a phase I trial. J Clin Oncol 19:127–136PubMedGoogle Scholar
  90. 90.
    Armstrong J, Raben A, Zelefsky M et al (1997) Promising survival with three-dimensional conformai radiation therapy for non-small cell lung cancer. Radiother Oncol 44: 17–22PubMedCrossRefGoogle Scholar
  91. 91.
    Socinski MA, Rosenman JG, Schell MJ et al (2000) Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformai thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I trial. Cancer 89:534–542PubMedCrossRefGoogle Scholar
  92. 92.
    Le Chevalier T, Brisgand D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367PubMedGoogle Scholar
  93. 93.
    Cardenal F, Lopez-Cabrerizo MP, Anton A et al (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17: 12–18PubMedGoogle Scholar
  94. 94.
    Crino L, Scagliotti GV, Ricci S et al (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522–3530PubMedGoogle Scholar
  95. 95.
    Masuda N, Fukuoka M, Negoro S et al (1999) Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a Multicenter phase III study (abstract). American Society of Clinical Oncology, Atlanta, p 459AGoogle Scholar
  96. 96.
    Bonomi P, Kim K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–631PubMedGoogle Scholar
  97. 97.
    Cornelia P, Frasci G, Panza N et al (2000) Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 18:1451–1457Google Scholar
  98. 98.
    Kosmidis P (2000) Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small-cell lung cancer. Oncology (Huntingt) 14:41–48Google Scholar
  99. 99.
    Georgoulias V, Papadakis E, Alexopoulos A et al (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478–1484PubMedCrossRefGoogle Scholar
  100. 100.
    Rodriguez J, Pawel J, Pluzanska A et al (2001) A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer (abstract). American Society of Clinical Oncology, San Fracsisco, p 314AGoogle Scholar
  101. 101.
    Hainsworth JD, Thompson DS, Greco FA (1995) Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13:1609–1614PubMedGoogle Scholar
  102. 102.
    Cerny T, Kaplan S, Pavlidis N et al (1994) Docetaxel (taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 70:384–387PubMedCrossRefGoogle Scholar
  103. 103.
    Anderson H, Lund B, Bach F et al (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1821–1826PubMedGoogle Scholar
  104. 104.
    Vokes EE (1995) Integration of vinorelbine into chemotherapy strategies for non-small-cell lung cancer. Oncology (Huntingt) 9:565–574, 577; discussion 577-578, 581Google Scholar
  105. 105.
    Fukuoka M, Niitani H, Suzuki A et al (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16–20PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • E. E. W. Cohen
  • E. E. Vokes

There are no affiliations available

Personalised recommendations